First Clinical Experiences With Fycompa® (perampanel) Show "Clear Therapeutic Benefit" (y 2)

        
        - Zonegran(R) (zonisamide) as monotherapy and adjunctive therapy in adult
          patients with partial-onset seizures, with or without secondary generalisation.
          (Zonegran is under license from the originator Dainippon Sumitomo Pharma). In
          Switzerland, Zonegran is only approved as adjunctive therapy.
        - Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients
          with partial-onset seizures, with or without secondary generalisation. (Zebinix is
          under license from BIAL). Zebinix is not approved by Swissmedic.
        - Inovelon(R) (rufinamide) for the adjunctive treatment of seizures associated
          with Lennox-Gastaut Syndrome in patients >4 years
        - Fycompa(R) (perampanel) for use as an adjunctive treatment for partial onset
          seizures, with or without secondarily generalised seizures, in patients with epilepsy
          aged 12 years and older

About Eisai

Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies.

Eisai concentrates its R&D activities in three key areas:

        
        - Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
          loss
        - Oncology including: anticancer therapies; tumour regression, tumour
          suppression, antibodies, etc
        - Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
          arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East and Africa (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium and the Middle East.

For further information please visit our web site http://www.eisai.co.uk

References

1. Geithner J, Frenck W, Holtkamp M. Effectiveness and side effects of perampanel: a first utilization study. Poster P06 presented at 8th joint three country meeting of the German and Austrian Societies for Epileptology and the Suisse League against Epilepsy, Interlaken, Switzerland 2013

2. Steinhoff BJ et al. First clinical experiences with perampanel. Poster P08 presented at 8th joint three country meeting of the German and Austrian Societies for Epileptology and the Suisse League against Epilepsy, Interlaken, Switzerland 2013

3. EMA Authorisation Details: http://www.ema.europa.eu/ema/index.jsp?c... [Last accessed April 2013]

4. Rogawski MA. Epilepsy Currents 2011;11:56-63

5. Fycompa Summary of Product Characteristics. 2012

6. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510... [Accessed August 2012]

7. Pugliatti M, et al. Epilepsia Estimating the cost of epilepsy in Europe: a review with economic modelling. 2007: 48(12);2224-2233

        
        Date of preparation: May 2013
        Job code: perampanel-UK2126

CONTACT: Media Enquiries, Eisai Europe Ltd, Charlotte Andrews / CressidaRobson, +44(0)7908-314-155, Cressida_Robson@eisai.net,Charlotte_andrews@eisai.net; Tonic Life Communications, Siobhan Reilly /Nicola Lilley, +44(0)207-798-999/+44(0)207-798-9905,siobhan.reilly@toniclc.com, nicola.lilley@toniclc.com